New York, January 17, 2026, 10:34 EST — Market closed
- On Friday, JNJ shares closed roughly 0.4% lower, ending the day at $218.66.
- Johnson & Johnson released new late-stage trial data on its Caplyta depression treatment. (Johnson & Johnson Investor Relations)
- U.S. markets will be closed Monday. J&J is set to report earnings on Jan. 21 before the opening bell. (New York Stock Exchange)
Johnson & Johnson shares edged down 0.41% Friday, finishing at $218.66, as U.S. healthcare stocks struggled. Pfizer slipped 0.93%, while Merck tumbled 1.93% during the session. (MarketWatch)
The market pulled back amid choppy trading ahead of the long weekend. The S&P 500 finished almost unchanged, with the healthcare sector dragging indexes lower. Investors are bracing for a busy earnings slate, including Johnson & Johnson’s report. “One of the other reasons markets have been flat-lining is we’re at the start of the earnings season,” said Anthony Saglimbene, chief market strategist at Ameriprise Financial. (Reuters)
Traders are clinging tightly to company guidance to keep the tape steady. “It is literally an imperative that earnings actually carry the news cycle,” said Art Hogan, chief market strategist at B Riley Wealth. Chris Fasciano, chief market strategist at Commonwealth Financial Network, was even more direct: “the most important thing right now is earnings.” (Reuters)
Johnson & Johnson on Friday released fresh data from Phase 3 trials of Caplyta in major depressive disorder, the late-stage studies backing approval efforts. The company reported that Caplyta, when added to an antidepressant, boosted remission rates over placebo at six weeks. In a six-month open-label extension, where patients knew their treatment, 65% achieved remission. “Remission is within reach and should be the expectation, not the exception,” said Bill Martin, J&J’s global head of neuroscience. The FDA approved Caplyta as an adjunctive therapy for MDD in November 2025. (Jnj)
Investors are keen to hear how management characterizes the early commercial progress of Caplyta and its implications for the wider neuroscience pipeline. Attention will also center on the company’s view of demand across both its drug portfolio and medical devices segment as it outlines guidance for 2026.
The short week brings a timing challenge. U.S. stock and bond markets will remain closed Monday, Jan. 19, in observance of Martin Luther King Jr. Day, reopening for normal trading on Tuesday. (Investopedia)
JNJ usually holds steady during volatile sessions, yet it still dips when the sector pulls back or money shifts toward higher-beta stocks. As earnings approach, even minor shifts in pricing, volume, or cost outlooks can push this typically slow-moving stock.
The downside is clear-cut: a cautious outlook or hints of slowing growth drivers could swiftly shift expectations. Plus, clinical-trial successes don’t always lead to widespread prescriptions, particularly in saturated markets.
Johnson & Johnson’s next major event is its fourth-quarter 2025 earnings call, set for Jan. 21 at 8:30 a.m. ET. Investors will be focused on the quarterly results, the outlook for the full year, and any updates management might provide on new product launches and the pipeline. (Johnson & Johnson Investor Relations)
